Treatment of Acute Lymphoblastic Leukemia – 30 Years' Experience at St. Jude Children's Research Hospital

New England Journal of Medicine

Volumn 329, Issue 18, 1993, Pages 1289-1295

  Rivera, Gaston K ^a,c   Pinkel, Donald ^d   Simone, Joseph V ^e   Hancock, Michael L ^b   Crist, William M ^a,c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b University of Tennessee   (United States)

^c Neuroscience Institute   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; EPIPODOPHYLLOTOXIN; METHOTREXATE; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BRAIN LEUKEMIA; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; DRUG MIXTURE; FEMALE; HUMAN; INFANT; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SECOND CANCER;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMAN; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0027497166     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199310283291801     Document Type: Article

References (42)

1. Clavell LA, Gelber RD, Cohen HJ, Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 1986; 315: 657-663
2. Gaynon PS, Steinherz PG, Bleyer WA, Intensive therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features: early conclusions of study CCG-106 by the Childrens Cancer Study Group. Lancet 1988; 2: 921-924
3. Riehm H, Gadner H, Henze G, Results and significance of six randomized trials in four consecutive ALL-BFM studies. Hamatol Bluttransfus 1990; 33: 439-450
4. Rivera GK, Raimondi SC, Hancock ML, Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991; 337: 61-66
5. Ochs J, Mulhern R, Fairclough D, Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: a prospective study. J Clin Oncol 1991; 9: 145-151
6. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808-815
7. Pui C-H, Ribeiro RC, Hancock ML, Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991; 325: 1682-1687
8. Pinkel D Five-year follow-up of “total therapy” of childhood lymphocytic leukemia. JAMA 1971; 216: 648-652
9. Pinkel D, Hernandez K, Borella L, Drug dosage and remission duration in childhood lymphocytic leukemia. Cancer 1971; 27: 247-256
10. Aur RJ, Simone J, Hustu HO, Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia. Blood 1971; 37: 272-281
11. Aur RJ, Simone JV, Hustu HO, Verzosa MS A comparative study of central nervous system irradiation and intensive chemotherapy early in remission of childhood acute lymphocytic leukemia. Cancer 1972; 29: 381-391
12. Simone JV Factors that influence haematological remission duration in acute lymphocytic leukaemia. Br J Haematol 1976; 32: 465-472
13. Aur RJ, Simone JV, Verzosa MS, Childhood acute lymphocytic leukemia: study VIII. Cancer 1978; 42: 2123-2134
14. Pui C-H, Aur RJ, Bowman WP, Failure of late intensification therapy to improve a poor result in childhood lymphoblastic leukemia. Cancer Res 1984; 44: 3593-3598
15. Murphy SB, Yatsula K, Thompson EI, Hayes FA, Simone JV Life after cancer. N Engl J Med 1986; 314: 188-188
16. Peto R, Pike MC, Armitage P, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39
17. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980.
18. Cox DR Regression models and life-tables. J R Stat Soc [B] 1972; 34: 187-202
19. Evans WE, Crom WR, Abromowitch M, Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. N Engl J Med 1986; 314: 471-477
20. 9/L. J Clin Oncol 1987; 5: 1015-1021
21. Rivera G, Aur RJ, Dahl GV, Second cessation of therapy in childhood lymphocytic leukemia. Blood 1979; 53: 1114-1120
22. Pui C-H, Bowman WP, Ochs J, Dodge RK, Rivera GK Cyclic combination chemotherapy for acute lymphoblastic leukemia recurring after elective cessation of therapy. Med Pediatr Oncol 1988; 16: 21-26
23. Rivera GK Cyclophosphamide and bone marrow transplantation. N Engl J Med 1988; 318: 1541-1541
24. Rivera GK The epipodophyllotoxin teniposide in therapy for childhood acute lymphocytic leukemia. J Clin Oncol 1988; 6: 191-193
25. Hammond D, Sather H, Nesbit M, Analysis of prognostic factors in acute lymphoblastic leukemia. Med Pediatr Oncol 1986; 14: 124-134
26. Hughes WT, Kuhn S, Chaudhary S, Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1977; 297: 1419-1426
27. Schriock EA, Schell MJ, Carter M, Hustu O, Ochs JJ Abnormal growth patterns and adult short stature in 115 long-term survivors of childhood leukemia. J Clin Oncol 1991; 9: 400-405
28. Mulhern RK, Wasserman AL, Fairclough D, Ochs J Memory function in disease-free survivors of childhood acute lymphocytic leukemia given CNS prophylaxis with or without 1,800 cGy cranial irradiation. J Clin Oncol 1988; 6: 315-320
29. Pinkel D Therapy of acute lymphoid leukemia in children. Leukemia 1992; 6: Suppl 2: 127-131
30. Skipper HE, Schabel FM Jr, Wilcox WS Experimental evaluation of potential anticancer agents. XIV. Further study of certain basic concepts underlying chemotherapy of leukemia. Cancer Chemother Rep 1965; 45: 5-28
31. Goldie JH, Coldman AJ, Gudauskas GA Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 1982; 66: 439-449
32. Camitta BM, Pinkel D, Thatcher LG, Casper J, Kun LE, Lauer S Failure of early intensive chemotherapy to improve prognosis in childhood acute lymphocytic leukemia. Med Pediatr Oncol 1980; 8: 383-389
33. Trueworthy R, Shuster J, Look T, Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study. J Clin Oncol 1992; 10: 606-613
34. Look AT, Roberson PK, Murphy SB Prognostic value of cellular DNA content in acute lymphoblastic leukemia of childhood. N Engl J Med 1987; 317: 1666-1666
35. Pullen J, Boyett J, Shuster J, Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol 1993; 11: 839-849
36. Bleyer WA, Poplack DG Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. Semin Oncol 1985; 12: 131-148
37. Niemeyer CM, Gelber RD, Tarbell NJ, Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (Protocol 81-01 update). Blood 1991; 78: 2514-2519
38. Niemeyer CM, Reiter A, Riehm H, Donnelly M, Gelber RD, Sallan SE Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukemia: the Berlin-Frankfurt-Munster and Dana-Farber Cancer Institute protocols. Ann Oncol 1991; 2: 745-749
39. Eguiguren JM, Schell MJ, Crist WM, Kunkel K, Rivera GK Complications and outcome in childhood acute lymphoblastic leukemia with hyperleukocytosis. Blood 1992; 79: 871-875
40. bcr-abl protein. Proc Natl Acad Sci U S A 1992; 89: 1468-1472
41. Campana D, Coustan-Smith E, Janossy G The immunologic detection of minimal residual disease in acute leukemia. Blood 1990; 76: 163-171 [Erratum, Blood 1990;76:1901.]
42. Evans WE Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose-intensity. Blut 1988; 56: 241-248